DEPRESSION RESEARCH
$975,439 awarded to research since 1985
16 million American adults live with major depression. Once thought of as simply “feeling blue,” it is now better understood that the word “depression” describes a family of very real mood disorders. While the symptoms and contexts of these illnesses vary, they can include prolonged periods of sadness or despair, detachment, loss of appetite, trouble sleeping, or thoughts of suicide. Depression represents the Foundation’s single greatest area of investment, in hopes of finding treatments—and maybe even cures—for these difficult, often lifelong conditions.
Active Research
Depression in the Menopause Transition: Stress and Inflammation as Pathways of Risk | Fiacco | $31,107
Depression in the Menopause Transition: Stress and inflammation as pathways of risk 2020 Award: $31,107 In the transition to menopause (perimenopause), depressive symptoms are very common and there is a 2-4 fold increased risk to [...]
Achieving Synergy with Multimodal Brain Stimulation: Electricity meets Magnetism | Frohlich | $156,613
Achieving Synergy with Multimodal Brain Stimulation: Electricity meets Magnetism 2016 Award: $156,613 Dr. Frohlich’s current exploration of noninvasive brain stimulation began with a Foundation grant in 2012, and continued in 2015 with an additional [...]
Mechanism of Action of Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder | Frohlich | $100,000
Mechanism of Action of Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder 2018 Award: $100,000 Major depressive disorder (MDD) has devastating effects on patients and their families, including an increased risk [...]
The Genomics of Severe Major Depressive Disorder (MDD) and Response to Electroconvulsive Therapy (ECT) | Soda | $39,990
The Genomics of Severe Major Depressive Disorder (MDD) and Response to Electroconvulsive Therapy (ECT) 2018 Award: $39,990 Depression is the leading cause of disability worldwide. It can lead to suicide which is the second [...]